Back to Results
First PageMeta Content
Periodontitis / Chronic periodontitis / Periodontal disease / Ondine / Food and Drug Administration / Scaling and root planing / Undine / Periodontology / Dentistry / Medicine / Health


510(k) - NSE - PMA - de novo
Add to Reading List

Document Date: 2010-07-19 15:50:55

Open Document

File Size: 29,33 KB

Share Result on Facebook

City

St Michael / Vancouver / Redmond / /

Company

UCL Business plc / Ondine Biopharma Corp. / /

Country

Barbados / United States / Canada / /

Event

FDA Phase / /

Facility

Eastman Dental Institute / University College London / /

IndustryTerm

photodisinfection technology / care for treating periodontal disease / light-activated technology / platform technology / /

MedicalCondition

Periodontitis / premature births / disease / Periodontal Disease Periodontitis / stroke / tooth loss / heart disease / diabetes / fungal and viral infections / gum disease / chronic adult periodontal disease / chronic periodontitis / periodontal disease / /

MedicalTreatment

antibiotic therapies / surgery / /

Organization

University College London / FDA / Eastman Dental Institute / European Union / /

Person

Michael Wilson / Carolyn Cross / /

Position

Governor / Professor / President and CEO / /

Product

Periowave / Canada / /

ProvinceOrState

British Columbia / Washington / /

Technology

lasers / platform technology / photodisinfection technology / light-activated technology / /

URL

www.ondinebiopharma.com / www.fda.gov / www.periowave.com / /

SocialTag